Skip to main content
SHENZHEN NEPTUNUS BIOENGINEERING CO.,LTD logo

SHENZHEN NEPTUNUS BIOENGINEERING CO.,LTD — Investor Relations & Filings

Ticker · 000078 ISIN · CNE000000X95 LEI · 300300J4GCOV7CYQTB51 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,614 across all filing types
Latest filing 2026-04-29 Annual Report
Country CN China
Listing Shenzhen Stock Exchange 000078

About SHENZHEN NEPTUNUS BIOENGINEERING CO.,LTD

https://www.neptunusbio.com

Shenzhen Neptunus Bioengineering Co., Ltd. is a comprehensive healthcare enterprise focused on the research, development, manufacturing, and distribution of pharmaceutical products. The company operates across the entire industry value chain, including the production of chemical drugs, biological preparations, and traditional Chinese medicines. Its portfolio extends to medical devices and health supplements. A significant component of its operations involves a large-scale pharmaceutical distribution network and a nationwide retail pharmacy chain. The company emphasizes innovation in biotechnology and maintains modern production facilities to support its diverse product lines. By integrating R&D with a robust logistics and retail infrastructure, it provides a wide range of healthcare solutions to medical institutions and consumers.

Recent filings

Filing Released Lang Actions
2025年年度报告
Annual Report Classification · 100% confidence The document is titled "深圳市海王生物工程股份有限公司2025年年度报告全文" which translates to "Shenzhen Neptunus Bioengineering Co., Ltd. 2025 Annual Report Full Text." It contains detailed sections typical of an annual report, including company overview, financial data for the full fiscal year 2025 (January 1 to December 31), management discussion and analysis, governance, financial statements, audit opinions, and other comprehensive disclosures. The document is about 15,000 characters long, indicating it is a full report rather than a brief announcement. It includes audited financial data, management commentary, and detailed business and industry analysis. The presence of an audit report with qualifications and internal control opinions further confirms this is a full annual report. Therefore, the document fits the definition of an Annual Report (10-K). FY 2025
2026-04-29 Chinese
关于2025年年度报告及2026年第一季度报告预约披露时间变更的公告
Report Publication Announcement Classification · 100% confidence The document is a short announcement (577 characters) from Shenzhen Haiwang Bioengineering Co., Ltd. It states a change in the scheduled disclosure dates for the 2025 Annual Report and the 2026 First Quarter Report. The text apologizes for the delay and informs investors about the new disclosure date. There is no actual financial data or report content included, only a notice about the timing change of report publication. According to the 'MENU VS MEAL' rule, this is not the report itself but an announcement about the report's publication timing. Therefore, the correct classification is Report Publication Announcement (RPA).
2026-04-28 Chinese
关于新增累计诉讼、仲裁情况的公告
Legal Proceedings Report Classification · 95% confidence The document is an announcement from Shenzhen Haiwang Bioengineering Co., Ltd. regarding the company's cumulative litigation and arbitration cases over the past twelve months. It provides detailed statistics on the number and amounts of lawsuits and arbitration cases involving the company as plaintiff and defendant, including case progress and potential impact on profits. The document is a regulatory disclosure about legal proceedings affecting the company, not a full audit report or annual report. It does not contain financial statements or management discussion of financial results but focuses on legal matters and compliance with stock exchange listing rules. Therefore, it fits the category of Legal Proceedings Report (LTR). The document length is 2435 characters, which is sufficient for a detailed announcement but not a full financial report. Hence, the classification is LTR with high confidence.
2026-04-24 Chinese
2026年第二次临时股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 92% confidence The document is the official announcement of resolutions passed at the company’s 2026 second Extraordinary Shareholders’ Meeting, detailing voting procedures, attendance, and vote counts on each proposal. This aligns with Declaration of Voting Results & Voting Rights Announcements (DVA).
2026-04-17 Chinese
北京德恒（深圳）律师事务所关于深圳市海王生物股份有限公司2026年第二次临时股东会的法律意见
Declaration of Voting Results & Voting Rights Announcements Classification · 92% confidence The document is a legal opinion letter from a law firm concerning the convening, procedures, and voting outcomes of a 2026 extraordinary shareholders’ meeting. It provides detailed vote counts and confirms the validity of resolutions passed, which aligns with the definition of “Declaration of Voting Results & Voting Rights Announcements” covering official vote results at AGMs or EGMs.
2026-04-17 Chinese
关于为控股子公司提供担保实施情况的公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement from Shenzhen Haiwang Bioengineering Co., Ltd. regarding the implementation of guarantees provided for its controlling subsidiaries. It lists specific guarantee contracts signed with various banks for credit facilities extended to subsidiaries, including amounts, contract terms, and guarantee scope. The document is an official disclosure about the company's guarantee activities to support subsidiaries' financing needs. It does not contain financial statements, audit opinions, or management discussions of financial results. It is not a report like an Annual Report, Interim Report, or Earnings Release. It is also not a regulatory certification or a short announcement of a report publication. The content fits the category of a Regulatory Filing (RNS) as it is a general regulatory announcement about guarantee activities and does not fit other more specific categories such as Capital/Financing Update (CAP) because it is about guarantees rather than new financing or capital changes. Therefore, the best classification is Regulatory Filings (RNS). The document length (7137 characters) and detailed content confirm it is a substantive regulatory announcement rather than a brief notice or report publication announcement.
2026-04-03 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.